Medicinova

MediciNova approved new employment agreements for President/CEO Dr. med. Dr. Yuichi Iwaki and CMO Dr. med. Dr. Kazuko Matsuda effective August 17, 2026, providing fixed annual salaries of $690,246 (Iwaki) and $540,143 (Matsuda) and performance-based annual bonuses (target: 55% and 40% of base salary, respectively). Both contracts replace prior arrangements, include severance payments for involuntary termination without cause and tiered, substantially higher payouts plus accelerated equity vesting for terminations related to a change of control; they also include a one-year post-contract non-solicitation clause and are governed by Delaware law. Despite 584% revenue growth last year, MediciNova remains unprofitable; analysts' price targets range from $6 to $11. » Plus sur de.investing.com

MediciNova reports that the SEANOBI-ALS study of MN-166 (Ibudilast) has reached its recruitment target of 200 patients under the Expanded Access Program. The study is funded by the National Institute of Neurological Disorders and Stroke and the NIH under the "ACT for ALS" program; final follow-ups are expected to conclude in early 2027 and trigger the start of data analysis. MN-166 is an orally active PDE4 and cytokine inhibitor with orphan and Fast Track designations, and analyst price targets for the stock range from $6 to $11, well above the current share price of $1.37. » Plus sur de.investing.com

MediciNova has filed preliminary, unaudited financial results for the fiscal year ended December 31, 2025, as part of Japan’s Kessan Tanshin, and notes that the figures may change materially upon completion of the annual audit. The independent auditor has not completed its review and has not issued an opinion or assurance on the preliminary results. In addition, MediciNova reports completion of patient recruitment for the Phase‑2b/3 COMBAT‑ALS trial of MN‑166, a mid‑point in the SEANOBI study, and completion of the OXTOX study; it also entered into a $50 million equity distribution agreement with Lucid Capital Markets. » Plus sur de.investing.com